| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/12/2012 | US8198067 Delivery of disease control in aquaculture and agriculture using microbes containing bioactive proteins |
| 06/12/2012 | US8197848 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 06/12/2012 | US8197839 A miniature coated tablet or covered rod implant; smaller size and larger payloads than immediate release tablets; veterinary medicine |
| 06/12/2012 | US8197826 Probiotic for enhancing immune response |
| 06/12/2012 | US8197553 Composite scaffolds and methods using same for generating complex tissue grafts |
| 06/12/2012 | US8197430 Method and system to remove cytokine inhibitor in patients |
| 06/12/2012 | CA2681962C Methods of administering epothilone analogs for the treatment of cancer |
| 06/12/2012 | CA2481486C Multi-phase, multi-compartment capsular system |
| 06/07/2012 | WO2012074754A1 Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors |
| 06/07/2012 | WO2012074137A1 Method for evaluating drug sensitivity by voltage-dependent calcium channel genetic analysis |
| 06/07/2012 | WO2012074116A1 IMMUNOTHERAPY USING ALLO-NKT CELLS, CELLS FOR IMMUNOTHERAPY IN WHICH α CHAIN OF T-CELL RECEPTOR (TCR) GENE HAS BEEN REARRANGED TO UNIFORM Vα-Jα, AND BANKING OF NKT CELLS DERIVED FROM SAID CELLS |
| 06/07/2012 | WO2012074085A1 Marker for determination of sensitivity to triplet combination anti-cancer agent |
| 06/07/2012 | WO2012072505A1 Volasertib alone or in combination with cytarabine for treating acute myeloid leukemia |
| 06/07/2012 | WO2012020123A9 Neuropilin as a biomarker for bevacizumab combination therapies |
| 06/07/2012 | US20120142614 Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis |
| 06/07/2012 | US20120142589 Tissue-protective cytokines for the protection, restoration and enhancement of responsive cells, tissues and organs |
| 06/07/2012 | US20120141608 Systemic administration of nac as an adjunct in the treatment of bioterror exposures such as anthrax, virus or radiation and use in combination with dhea for the treatment of viruses |
| 06/07/2012 | US20120141560 Tumor and infectious disease therapeutic compositions |
| 06/07/2012 | US20120141558 Alginate-based nanofibers and related scaffolds |
| 06/07/2012 | US20120141499 Specific binding agents of human angiopoietin-2 |
| 06/07/2012 | US20120141470 T cell inhibitory receptor compositions and uses thereof |
| 06/07/2012 | US20120141428 Muscle-derived cells (mdcs) for treating muscle- or bone-related injury or dysfunction |
| 06/07/2012 | US20120141411 Uses of IL-174 Antagonists for Inhibiting A Th2 Immune Response |
| 06/07/2012 | US20120141379 Microspheres for active embolization |
| 06/07/2012 | US20120138506 Methods of treatment and pharmaceutical composition |
| 06/07/2012 | CA2819399A1 Marker for determination of sensitivity to triplet combination anti-cancer agent |
| 06/07/2012 | CA2817968A1 Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors |
| 06/06/2012 | EP2460529A1 Therapeutic agent and therapeutic method for periodontal diseases and pulpal diseases |
| 06/06/2012 | EP2460528A1 Therapeutic agent and therapeutic method for periodontal diseases and pulpal diseases |
| 06/06/2012 | EP2460522A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| 06/06/2012 | EP2459589A1 Mutants pf4 polypeptides exhibiting an increased anti-angiogenic activity |
| 06/06/2012 | EP2459216A2 Immunogenic compositions including tlr activity modulators |
| 06/06/2012 | EP2459187A1 Compositions and methods for inhibiting hair growth |
| 06/06/2012 | EP2459183A1 Methods for treatment of pain |
| 06/06/2012 | EP2240155B1 Devices, formulations, and methods for delivery of multiple beneficial agents |
| 06/06/2012 | EP1967209B1 Therapeutic agent for prostate cancer |
| 06/06/2012 | EP1863493B1 Corticosteroid containing formulation for treating psoriasis, eczema, ulcer and burns. |
| 06/06/2012 | EP1789433B1 Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| 06/06/2012 | EP1718265B1 Canine probiotic bifidobacteria globosum |
| 06/06/2012 | EP1616575B1 Method for treating inflammation |
| 06/06/2012 | EP1548024B1 Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| 06/06/2012 | CN1984682B Solid medicinal preparation |
| 06/06/2012 | CN102008725B Application of human UTP14a expression inhibitor in preparation of cell proliferation inhibitor |
| 06/06/2012 | CN101228183B Method of purifying APO-2 ligand/TRAIL using crystallisation in the cold |
| 06/05/2012 | US8193332 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| 06/05/2012 | US8193326 Nucleotide sequences coding oncogenic polypeptides for use in generating vaccines to prevent and treat cell proliferative disorders; genetic vaccines |
| 06/05/2012 | US8193249 Triptolide analogs for the treatment of autoimmune and inflammatory disorders |
| 06/05/2012 | US8193209 Analgesic combination of oxycodone and meloxicam |
| 06/05/2012 | US8193201 Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines |
| 06/05/2012 | US8193172 Administering a steroid |
| 06/05/2012 | US8192964 Safflower with elevated gamma-linolenic acid |
| 06/05/2012 | US8192756 Gastric retained gabapentin dosage form |
| 06/05/2012 | CA2670236C Therapeutic treatment of androgen receptor driven conditions |
| 06/05/2012 | CA2482041C 4-chromanone derivatives for treating cellular proliferative diseases and disorders |
| 06/05/2012 | CA2435419C Halogenated composition, method for preparing same and uses thereof |
| 06/05/2012 | CA2435375C Mammalian tumor susceptibility gene products and their uses |
| 06/05/2012 | CA2431207C Compositions containing inclusion complexes |
| 06/05/2012 | CA2418238C Method for treating unstable angina pectoris |
| 06/05/2012 | CA2292882C Mutant having uracil phosphoribosyl transferase activity |
| 06/05/2012 | CA2264939C Materials and methods relating to the diagnosis and treatment of pre-eclampsia and diabetes |
| 06/05/2012 | CA2233534C Manipulation of non-terminally differentiated cells using the notch pathway |
| 05/31/2012 | WO2012071269A2 Selective removal of cells having accumulated agents |
| 05/31/2012 | WO2012070601A1 Novel 2-alkynyl-n9-propargyladenine and medicinal use thereof |
| 05/31/2012 | WO2012069972A1 A pharmaceutical combination for the treatment of breast cancer |
| 05/31/2012 | WO2012069658A2 Immunomodulatory compositions |
| 05/31/2012 | WO2012069150A2 Cytoprotectant agents for the prevention of drug-associated side-effects |
| 05/31/2012 | WO2012007729A3 Pharmaceutical compositions comprising r (+) budesonide and one or more bronchodilators |
| 05/31/2012 | US20120136157 Aryl ureas as kinase inhibitors |
| 05/31/2012 | US20120135042 Methods Using Immunomodulatory Compounds For Treatment of Certain Leukemias |
| 05/31/2012 | DE102010052847A1 Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung A process for the preparation of a pharmaceutical preparation containing PPI- |
| 05/31/2012 | CA2856101A1 Immunomodulatory compositions |
| 05/31/2012 | CA2818647A1 Selective removal of cells having accumulated agents |
| 05/30/2012 | EP2457589A1 Reverse targeting lipid vesicle |
| 05/30/2012 | EP2457572A1 Use of atomic quantum clusters (aqcs) in the prevention of cell proliferative disorders, viral infections and autoimmune diseases |
| 05/30/2012 | EP2457566A1 EXTERNAL PREPARATION CONTAINING NSAIDs AND METHOD FOR PRODUCING THE EXTERNAL PREPARATION |
| 05/30/2012 | EP2456868A1 Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| 05/30/2012 | EP2456790A1 Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| 05/30/2012 | EP2456471A2 Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof |
| 05/30/2012 | EP2456444A1 Certain chemical entities, compositions and methods |
| 05/30/2012 | EP2456441A1 Combination therapies with ck2 modulators |
| 05/30/2012 | EP2456432A1 Methods and compositions to reduce oxidative stress |
| 05/30/2012 | EP2456431A1 Cell protection in dialysis patients by administration of a creatine compound |
| 05/30/2012 | EP2456409A1 Natural preservative blend |
| 05/30/2012 | EP2456310A1 Substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mglur4 potentiators |
| 05/30/2012 | EP2456306A1 Vitamin c and vitamin k, and compositions thereof for treatment of osteolysis or prolongation of prosthetic implant |
| 05/30/2012 | EP1558078B1 Acidified chlorite compositions containing nitrogenous stabilizers and systems and methods related thereto |
| 05/30/2012 | EP1405079B1 Modulation of the interaction between evh1 domains |
| 05/30/2012 | EP1283057B2 Cell proliferation inhibitors |
| 05/30/2012 | EP1263465B1 Photodynamic cellular organism eradication using a photosensitive material and surfactant |
| 05/30/2012 | CN1886506B Protein expressed in nk cell |
| 05/30/2012 | CN1852730B Modulators of P-selectin glycoprotein ligand 1 |
| 05/30/2012 | CN1726048B Gastric acid secretion inhibiting composition |
| 05/30/2012 | CN1684674B Therapeutic causing contraction of mucosal tissue, injector and therapeutic set |
| 05/30/2012 | CN102481369A 抗革兰氏阴性菌剂 Against gram-negative bacterium |
| 05/30/2012 | CN102481333A Immunity inducer |
| 05/30/2012 | CN102481302A Pharmaceutical combination for treating tumor |
| 05/30/2012 | CN102481299A 包括与第二抗增殖性试剂结合的(-)-反式-3-(5，6-二氢-4H-吡咯[3，2，1-ij]喹啉-1-基)-4-(1H-吲哚-3-基)吡咯烷-2，5-二酮的组合物 Including in combination with a second anti-proliferative agent (-) - trans-3- (5,6-dihydro--4H- pyrrolo [3,2,1-ij] quinolin-1-yl) -4- ( 1H- indol-3-yl) pyrrolidine-2,5-dione The composition of |
| 05/30/2012 | CN102481260A 抗干扰的剂型，其包括基质和包含药物的熔融挤出的颗粒 Interference dosage form comprising a drug-containing matrix and the melt extruded particles |
| 05/30/2012 | CN102475890A Acceptor protein, and coding gene and application thereof |
| 05/30/2012 | CN102475889A 治疗皮肤病的含辅料的分离式水混悬剂药物 Dermatology drugs separate aqueous suspensions containing excipients |